<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556098</url>
  </required_header>
  <id_info>
    <org_study_id>H-18002707</org_study_id>
    <nct_id>NCT03556098</nct_id>
  </id_info>
  <brief_title>Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes</brief_title>
  <official_title>Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present project the investigators will evaluate whether glucagonotropic properties of
      the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be
      utilized as a safeguard against hypoglycemia in patients with T1D.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blinded, randomized, cross-over study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The peptides/placebo is prepared, in a randomized fashion, by a laboratory assistant..</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>plasma glucose concentration</measure>
    <time_frame>At times (minute): - 30, - 15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240 on study days</time_frame>
    <description>plasma glucose excursions and plasma glucose nadir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose regulatory hormones</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 on study days</time_frame>
    <description>Counter regulatory hormones: glucagon, noradrenalin, cortisol, somatotropin, and insulin/c-peptide. Incremental and total area under the Concentration-Time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretin hormones</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 on study days</time_frame>
    <description>Incretin hormones GLP-1 and GIP. Incremental and total area under the Concentration-Time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP[3-30]</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 on study days</time_frame>
    <description>GIP[3-30]. Incremental and total area under the Concentration-Time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids (FFA)</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 on study days</time_frame>
    <description>Free fatty acids(FFA). Incremental and total area under the Concentration-Time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood analysis of paracetamol as an assessment of gastric emptying</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 on study days</time_frame>
    <description>Assessment of gastric emptying</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mRNA</measure>
    <time_frame>At time 240 minute on study days</time_frame>
    <description>Fat biopsy to evaluate changes in fat mRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Lipoprotein lipase (LPL)</measure>
    <time_frame>At time 240 minute on study days</time_frame>
    <description>Fat biopsy to evaluate LPL changes in fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Perilipin 4</measure>
    <time_frame>At time 240 minute on study days</time_frame>
    <description>Fat biopsy to evaluate Perilipin 4 changes in fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Fatty acid binding protein 4 (FABP4)</measure>
    <time_frame>At time 240 minute on study days</time_frame>
    <description>Fat biopsy to evaluate Fatty acid binding protein 4 (FABP4) changes in fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Hormonse-sensitive lipase (HSL)</measure>
    <time_frame>At time 240 minute on study days</time_frame>
    <description>Fat biopsy to evaluate Hormonse-sensitive lipase (HSL) changes in fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Vascular endothelial growth factor 4 (VEGF-A)</measure>
    <time_frame>At time 240 minute on study days</time_frame>
    <description>Fat biopsy to evaluate Vascular endothelial growth factor 4 (VEGF-A) changes in fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat GIP receptor (GIPR)</measure>
    <time_frame>At time 240 minute on study days</time_frame>
    <description>Fat biopsy to evaluate GIP receptor (GIPR) changes in fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 on study days</time_frame>
    <description>Changes in blood pressure, mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 on study days</time_frame>
    <description>Changes in pulse, beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia symptom score</measure>
    <time_frame>At times (minute): - 30, 0, 15, 30, 60, 90, 120, 150, 180, 210, 240 or when clinically relevant, based on the glucose nadir value on study days</time_frame>
    <description>Derived from Edinburgh Hypoglycemia Symptom Scale: Self-evaluated 18 symptoms all with a score from 1-7.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of Glucose-dependent insulinotropic peptide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP[3-30]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of GIP[3-30]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucose-dependent insulinotropic peptide</intervention_name>
    <description>Infusion of GIP</description>
    <arm_group_label>GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose-Dependent Insulin-Releasing Hormone[3-30]</intervention_name>
    <description>Infusion of GIP antagonist GIP[3-30]</description>
    <arm_group_label>GIP[3-30]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Infusion of Saline</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian men

          -  Body mass index between 20-27 kg/m^2

          -  T1D (diagnosed according to the criteria of the World Health Organization) with
             HbA1c&lt;69 mmol/l (&lt;8,5%)

          -  T1D duration between 2-20 years

          -  Stimulated C-peptide ≤ 100 pmol/mL)

          -  Treatment with a stable basal bolus or insulin pump regimen ≥ 3 months

          -  Informed consent

        Exclusion Criteria:

          -  Anemia (hemoglobin below normal range)

          -  Liver disease (ALAT and/or ASAT &gt;2 times normal values) or history of hepatobiliary
             disorder

          -  Nephropathy (serum creatinine above normal range and/or albuminuria)

          -  Allergy or intolerance to ingredients included in the standardized meals

          -  Prior myocardial infarction or other cardiac events

          -  Any physical or psychological condition that the investigator fells would interfere
             with trial participation

          -  Treatment with any glucose-lowering drugs beside insulin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Bjørn Hoe</investigator_full_name>
    <investigator_title>Medical Doctor, PhD student, Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Gastric Inhibitory Polypeptide</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Incretin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

